Financials Kyverna Therapeutics, Inc.

Equities

KYTX

US5019761049

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
15.41 USD +1.03% Intraday chart for Kyverna Therapeutics, Inc. +10.05% 0.00%

Valuation

Fiscal Period: December 2024 2025 2026
Capitalization 1 664.8 - -
Enterprise Value (EV) 1 469.1 526.5 466.7
P/E ratio -4.28 x -3.64 x -3.29 x
Yield - - -
Capitalization / Revenue 177 x 133 x 79.8 x
EV / Revenue 125 x 105 x 56 x
EV / EBITDA -3.23 x -2.67 x -2.19 x
EV / FCF -3.72 x -2.83 x -
FCF Yield -26.9% -35.3% -
Price to Book 6.12 x -8.52 x 119 x
Nbr of stocks (in thousands) 43,115 - -
Reference price 2 15.42 15.42 15.42
Announcement Date - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2022 2023 2024 2025 2026
Net sales 1 - - 3.75 5 8.333
EBITDA 1 - -60.7 -145.3 -197 -213.1
EBIT 1 - -62.41 -142.4 -199.3 -211.7
Operating Margin - - -3,796.91% -3,985.39% -2,540.87%
Earnings before Tax (EBT) 1 - -60.37 -139.8 -193.8 -218.5
Net income 1 -28.89 -60.37 -138.1 -196.8 -230.8
Net margin - - -3,683.8% -3,935.66% -2,770.07%
EPS 2 -13.94 -89.61 -3.602 -4.237 -4.685
Free Cash Flow 1 - -53.03 -126 -186 -
FCF margin - - -3,360% -3,720% -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 10/5/23 3/26/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - -
EBITDA 1 -20.92 - -36 -44 -51
EBIT 1 -21.38 -29.36 -34 -39.5 -44.5
Operating Margin - - - - -
Earnings before Tax (EBT) 1 - - -34 -41 -49
Net income 1 - - -31.8 -38.45 -45.75
Net margin - - - - -
EPS 2 -75.82 -1.120 -0.7531 -0.8627 -0.9934
Dividend per Share - - - - -
Announcement Date 3/26/24 5/14/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2022 2023 2024 2025 2026
Net Debt 1 - - - - -
Net Cash position 1 - - 196 138 198
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow 1 - -53 -126 -186 -
ROE (net income / shareholders' equity) - - -99.3% -648% -
ROA (Net income/ Total Assets) - - -79% -55.9% -
Assets 1 - - 174.8 352 -
Book Value Per Share 2 - - 2.520 -1.810 0.1300
Cash Flow per Share - - - - -
Capex 1 - 0.62 1.5 5 -
Capex / Sales - - 40% 100% -
Announcement Date 10/5/23 3/26/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
15.42 USD
Average target price
42.75 USD
Spread / Average Target
+177.24%
Consensus
  1. Stock Market
  2. Equities
  3. KYTX Stock
  4. Financials Kyverna Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW